Heinonen O P, Paunio M, Peltola H
Ann Med. 1998 Apr;30(2):131-3. doi: 10.3109/07853899808999395.
On average, 15,000 cases of measles occurred annually in Finland before the initiation of a vaccination programme in 1975. Because of insufficient activity, the vaccination coverage failed to reach the required level of over 90%, and cases continued to occur. The policy was revolutionized in 1982 by launching a project in which the Schwarz strain was substituted by an attenuated Enders-Edmonston strain given as a component of a trivalent live-virus measles-mumps-rubella vaccine (MMRII). This vaccine is given twice, at the ages of 14-18 months and 6 years. The impact of the vaccinations has been monitored in several prospective studies. In addition to a very favourable safety profile, good immunogenicity and excellent clinical effectiveness have also been demonstrated. Since 1996 not a single case of measles has been found in Finland, although cases have been searched actively and serological confirmation has been required. Total interruption of virus circulation has brought a new problem: the possibility of vaccinees to acquire natural boosters is so rare that waning immunity has become a reality. As there is a continuous risk of measles originating from a foreign source, the only tool against an outbreak is to maintain a high vaccination coverage and to continue the two-dose schedule as a minimum policy.
1975年芬兰启动疫苗接种计划之前,麻疹病例平均每年出现15000例。由于接种活动力度不足,疫苗接种覆盖率未能达到90%以上的要求水平,病例仍不断出现。1982年政策发生了变革,启动了一个项目,用减毒的恩德斯-埃德蒙斯顿毒株替代施瓦茨毒株,该毒株作为三价活病毒麻疹-腮腺炎-风疹疫苗(MMRII)的一个组分。这种疫苗接种两次,分别在14至18个月龄和6岁时。在多项前瞻性研究中对疫苗接种的影响进行了监测。除了具有非常良好的安全性外,还证明了其良好的免疫原性和出色的临床有效性。自1996年以来,芬兰未发现一例麻疹病例,尽管一直在积极搜索病例并要求进行血清学确认。病毒传播的完全中断带来了一个新问题:接种疫苗者获得自然增强免疫的可能性非常罕见,以至于免疫力下降已成为现实。由于存在来自国外的麻疹持续风险,应对疫情爆发的唯一手段是维持高疫苗接种覆盖率,并至少继续实施两剂次接种方案。